Summary
This prediction ended on 07.06.18 with a price of €27,600,000. With a performance of -9.21%, the BUY prediction for Neovacs by melinda closed slightly in the red. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Neovacs | - | - | - | - |
| iShares Core DAX® | 1,01 % | 2,70 % | 4,36 % | 51,69 % |
| iShares Nasdaq 100 | -6,47 % | -8,77 % | 18,00 % | 67,99 % |
| iShares Nikkei 225® | -6,52 % | -12,58 % | 40,91 % | 57,11 % |
| iShares S&P 500 | -2,72 % | -1,75 % | 16,97 % | 58,87 % |
According to melinda what are the pros and cons of Neovacs for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by melinda for this prediction
In the thread Neovacs diskutieren
Neovacs: Beginn der Spekulation vor klinischen Ergebnissen für LUPUS?

(Vom Mitglied beendet)


